Overview

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Rozanolixizumab Administered Subcutaneously Via Manual Push Versus Syringe Driver to Healthy Participants

Status:
Recruiting

Trial end date:
2022-01-01

Target enrollment:

Participant gender:

Summary

The purpose of the study is to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of a single subcutaneous (SC) dose of rozanolixizumab administered to healthy participants by manual push (MP) versus (vs) syringe driver.

Phase:

Phase 1

Details

Lead Sponsor:

UCB Biopharma SRL

Treatments:

Rozanolixizumab